Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 45-48

  Fountzilas, George ^a   Athanassiades, Athanassios ^a   Papadimitriou, Vasilios ^b   Dimopoulos, Meletios Athanassios ^b   Bafaloukos, Dimitrios ^c   Aravantinos, Gerasimos ^d   Nicolaides, Constantine ^e   Kalofonos, Haralambos ^f   Papakostas, Pavlos ^g   Xiros, Nicholaos ^h   Razi, Evalgelia ⁱ  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d AGII ANARGIRI CANCER HOSPITAL   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g HIPPOKRATION HOSPITAL   (Greece)

^h EVANGELISMOS HOSPITAL   (Greece)

ⁱ HYGEIA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; MITOXANTRONE; PACLITAXEL;

ADULT; ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARBOPLATIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL;

EID: 13144281701     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel (Taxol) N Engl J Med 332:1004-1014, 1995
2. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13 1152-1159, 1995.
3. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxombicin-refractory or mitoxantrone-refractory breast cancer: A phase I-II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994.
4. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995.
5. Gelmon KA: Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 22(suppl 12):117-122, 1995.
6. Wasserheit C, Frazein A, Oratz R, et al: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity. J Clin Oncol 14:1993-1999, 1996.
7. O'Brien MER, Talbot DC. Smith IE: Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11:2112-2117, 1993.
8. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, et al: Paclitaxel by 3-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 33:1893-1895, 1997.
9. Miller AB, Hoogsraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 47.207-214, 1981.
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
11. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.